Capricor Therapeutics, Inc. 2025 Annual Report – Key Highlights and Investor Insights

Overview

Capricor Therapeutics, Inc. (“Capricor” or “the Company”) has released its Form 10-K annual report for the fiscal year ended December 31, 2025. The report provides a comprehensive overview of the Company’s operations, financial status, and strategic direction, with important information for current and prospective investors.

Key Points for Shareholders

• Common Stock: As of March 16, 2026, Capricor had 57,510,635 shares of common stock outstanding, with a par value of \$0.001 per share.
• Market Capitalization: As of June 30, 2025, the aggregate market value of common stock held by non-affiliates was approximately \$398,991,720, based on a last reported sale price of \$9.93 per share on the Nasdaq Global Select Market.
• Exchange Listing: Capricor’s common stock is traded under the symbol CAPR on the Nasdaq Global Select Market.
• SEC Filing Status: The company is a “smaller reporting company” and is not considered a well-known seasoned issuer or an emerging growth company. Capricor is current with all required filings and has submitted all Interactive Data Files as required by SEC regulations.
• No Financial Restatements or Errors: The report confirms that there were no corrections of errors or restatements requiring recovery analysis of incentive-based compensation relating to financial statements.
• Internal Control: The company’s auditors did not provide an attestation report on internal control over financial reporting under Section 404(b) of Sarbanes-Oxley, consistent with the company’s status as a smaller reporting company.
• Legal Proceedings and Mine Safety: Capricor states its compliance with all legal requirements and mine safety disclosures, with no new significant legal or regulatory exposures reported.

Product Pipeline and Development Update

Capricor continues to advance its portfolio of product candidates, which are protected by over 150 granted patents and pending patent applications worldwide. The company’s pipeline is focused on innovative therapies in the biotechnology sector, with product candidates at various stages ranging from discovery to evaluation.

• Clinical Trials: The company actively registers and discloses information about its clinical trials, as per FDA and international requirements. Disclosure of trial results can be delayed up to two years post-completion, but Capricor notes that competitors may gain insight into its development programs from publicly available data.
• Regulatory Status: The company discusses the standard FDA review process for new drugs and biologics, including the possibility of receiving Complete Response Letters (CRLs) that may delay or condition approval. There is no indication in this report of new approvals or CRLs received during 2025.

Risks and Forward-Looking Statements

The company emphasizes that, while it is progressing in its clinical and regulatory activities, there remain significant risks and uncertainties. These include the success of ongoing and future clinical trials, ability to secure regulatory approvals, manufacturing and commercialization challenges, potential impact from regulatory authorities, and continued need to raise capital or secure strategic partnerships.

• Capricor highlights its intention to comply with the Private Securities Litigation Reform Act safe-harbor provisions for forward-looking statements, and reminds investors that past performance is not necessarily indicative of future results.
• The company does not undertake to update forward-looking statements unless required by law.

Matters That May Affect Share Value

• Market Capitalization and Share Count: The substantial market value and share count could affect liquidity and investor perception.
• Product Development Progress: Ongoing product development and the status of regulatory filings and approvals could significantly affect the company’s valuation, especially if there are delays or setbacks in clinical trials or the FDA approval process.
• Intellectual Property Portfolio: The breadth of Capricor’s patent portfolio is a competitive strength and a potential barrier to entry for competitors. Any material changes in patent status or litigation would be price-sensitive.
• Financial Position and Reporting: The company remains up-to-date with filings and is not a shell company or subject to restatement risks, which provides a degree of stability and transparency for investors.

Conclusion

Capricor Therapeutics, Inc. continues to operate as a development-stage biotechnology company with a robust patent portfolio and several product candidates in the pipeline. While the company did not report major new approvals or financial restatements, its ongoing compliance with SEC listing and reporting requirements, as well as its focus on intellectual property and product development, will be areas for investors to monitor closely. Any significant advancement in clinical trials or regulatory approvals would likely have a material impact on the share price.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full SEC filings, consider their own financial situation, and consult with their advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.

View CAPRICOR THERAPEUTICS, INC. Historical chart here